ArticleTargeted oncology2016

Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.

John Sarantopoulos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.